Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JCSH-021
- Development stage
- Unknown
- Lead developer
- Jichuan Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JCSH-021 is an investigational, orally administered small molecule drug candidate developed by Jichuan (Shanghai) Medical Technology, a subsidiary of Jichuan Pharmaceutical. It is classified as a Class 1 chemical innovative drug in China. In late 2026, the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) accepted and subsequently approved the Investigational New Drug (IND) application for JCSH-021 tablets. The primary indication for JCSH-021 is the treatment of moderate-to-severe atopic dermatitis. The specific biological target and detailed mechanism of action for JCSH-021 have not been publicly disclosed by the developer.
- Other names
- JCSH-021片JCSH021JCSH-021JCSH 021
Beyond the preview
Go deeper on JCSH-021.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JCSH-021.